WO2007027957A3 - Reagents for the detection of protein phosphorylation in leukemia signaling pathways - Google Patents

Reagents for the detection of protein phosphorylation in leukemia signaling pathways Download PDF

Info

Publication number
WO2007027957A3
WO2007027957A3 PCT/US2006/034126 US2006034126W WO2007027957A3 WO 2007027957 A3 WO2007027957 A3 WO 2007027957A3 US 2006034126 W US2006034126 W US 2006034126W WO 2007027957 A3 WO2007027957 A3 WO 2007027957A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
reagents
protein
phosphorylation
sites
Prior art date
Application number
PCT/US2006/034126
Other languages
French (fr)
Other versions
WO2007027957A2 (en
WO2007027957A9 (en
Inventor
Roberto Polakiewicz
Valerie Goss
Kimberly Lee
Ting-Lei Gu
Albrecht Moritz
Original Assignee
Cell Signaling Technology Inc
Roberto Polakiewicz
Valerie Goss
Kimberly Lee
Ting-Lei Gu
Albrecht Moritz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology Inc, Roberto Polakiewicz, Valerie Goss, Kimberly Lee, Ting-Lei Gu, Albrecht Moritz filed Critical Cell Signaling Technology Inc
Priority to EP06802749A priority Critical patent/EP1929305A2/en
Publication of WO2007027957A2 publication Critical patent/WO2007027957A2/en
Publication of WO2007027957A9 publication Critical patent/WO2007027957A9/en
Publication of WO2007027957A3 publication Critical patent/WO2007027957A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins.
PCT/US2006/034126 2005-08-31 2006-08-30 Reagents for the detection of protein phosphorylation in leukemia signaling pathways WO2007027957A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06802749A EP1929305A2 (en) 2005-08-31 2006-08-30 Reagents for the detection of protein phosphorylation in leukemia signaling pathways

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71277605P 2005-08-31 2005-08-31
US60/712,776 2005-08-31

Publications (3)

Publication Number Publication Date
WO2007027957A2 WO2007027957A2 (en) 2007-03-08
WO2007027957A9 WO2007027957A9 (en) 2007-05-31
WO2007027957A3 true WO2007027957A3 (en) 2009-01-29

Family

ID=37809538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034126 WO2007027957A2 (en) 2005-08-31 2006-08-30 Reagents for the detection of protein phosphorylation in leukemia signaling pathways

Country Status (2)

Country Link
EP (1) EP1929305A2 (en)
WO (1) WO2007027957A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8273544B2 (en) 2008-07-10 2012-09-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9182385B2 (en) 2007-08-21 2015-11-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383712T3 (en) 2001-01-17 2012-06-25 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
WO2009033234A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
ES2619681T3 (en) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novel epitopes P2X7
EP2599793A1 (en) * 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
JP5701752B2 (en) 2008-07-04 2015-04-15 バイオセプター・インターナショナル・リミテッド Anti-P2X7 peptide and epitope
EA027071B1 (en) * 2009-04-27 2017-06-30 Новартис Аг ANTI-ActRIIB ANTIBODY AND COMPOSITION COMPRISING SAME
WO2011020155A1 (en) 2009-08-20 2011-02-24 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
ES2732021T3 (en) 2009-12-24 2019-11-20 Biosceptre Aust Pty Ltd Non-functional oligomeric P2X7 receptor antibodies
ES2656971T3 (en) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Treatments for cancer in pets with an anti P2X7 antibody
BR112013033974A2 (en) 2011-07-01 2017-02-14 Biosceptre Int Ltd combination therapy
KR101478826B1 (en) * 2011-10-28 2015-01-08 전남대학교산학협력단 Newly identified colorectal cancer marker genes，proteins translated from the genes and a diagnostic kit using the same
EP2878306B1 (en) * 2012-07-13 2018-11-07 Proteimax Biotecnologia Ltda Modified peptide, cb receptor ligand, kit, in vitro process for evaluating cb receptor bonds, uses, pharmaceutical composition for modulating cb receptor activity
WO2017156488A2 (en) 2016-03-10 2017-09-14 Acceleron Pharma, Inc. Activin type 2 receptor binding proteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20030219838A1 (en) * 2002-05-24 2003-11-27 Johnson Richard S. Polypeptide analyses using stable isotope labeling
US20050003450A1 (en) * 1998-09-04 2005-01-06 John Rush Immunoaffinity isolation of modified peptides from complex mixtures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050003450A1 (en) * 1998-09-04 2005-01-06 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20030219838A1 (en) * 2002-05-24 2003-11-27 Johnson Richard S. Polypeptide analyses using stable isotope labeling

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9182385B2 (en) 2007-08-21 2015-11-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8273544B2 (en) 2008-07-10 2012-09-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8778620B2 (en) 2008-07-10 2014-07-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9500655B2 (en) 2008-07-10 2016-11-22 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Also Published As

Publication number Publication date
EP1929305A2 (en) 2008-06-11
WO2007027957A2 (en) 2007-03-08
WO2007027957A9 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2007027957A3 (en) Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007027867A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007027906A3 (en) Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008009002A3 (en) Reagents for the detection of protein phosphorylation in signaling pathways
US20220260581A1 (en) Peptide constructs and assay systems
WO2008009004A3 (en) Reagents for the detection of protein phosphorylation in signaling pathways
WO2006086111A3 (en) Reagents for the detection of protein phosphorylation in leukemia signaling pathways
Pickart et al. Polyubiquitin chains: polymeric protein signals
WO2007133702A3 (en) Reagents for the detection of protein acetylation signaling pathways
WO2008008998A3 (en) Reagents for the detection of protein phosphorylation in signaling pathways
WO2007127335A3 (en) Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2006031800A3 (en) Reverse transfection of cell arrays
JP2006225396A5 (en)
WO2004062475A3 (en) Fluorescent assays for protein kinases
US20230279386A1 (en) Methods for preparing analytes and related kits
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
WO2008009000A3 (en) Reagents for the detection of protein phosphorylation in signaling pathways
US20210254047A1 (en) Proximity interaction analysis
WO2007133688A3 (en) Reagents for the detection of tyrosine phosphorylation in brain ischemia signaling pathways
WO2000022166A3 (en) Genes for assessing cardiovascular status and compositions for use thereof
WO2007133689A3 (en) Reagents for the detection of protein acetylation signaling pathways
EP4073263A1 (en) Methods for stable complex formation and related kits
WO2006113050A8 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CN112236450A (en) Compositions of target binding moieties and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006802749

Country of ref document: EP